Is Avenue Therapeutics Stock a Good Investment?
Avenue Therapeutics Investment Advice | ATXI |
- Examine Avenue Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Avenue Therapeutics' leadership team and their track record. Good management can help Avenue Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Avenue Therapeutics' business and its evolving consumer preferences.
- Compare Avenue Therapeutics' performance and market position to its competitors. Analyze how Avenue Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Avenue Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Avenue Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Avenue Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Avenue Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Avenue Therapeutics Stock
Researching Avenue Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 1.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. Avenue Therapeutics recorded earning per share (EPS) of 24.78. The entity had not issued any dividends in recent years. The firm had 1:75 split on the 26th of April 2024.
To determine if Avenue Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avenue Therapeutics' research are outlined below:
| Avenue Therapeutics generated a negative expected return over the last 90 days | |
| Avenue Therapeutics has high historical volatility and very poor performance | |
| Avenue Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Avenue Therapeutics currently holds about 890 K in cash with (9.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Avenue Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Therapeutics Inc |
Avenue Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avenue Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avenue Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Avenue Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Avenue Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-16 | 2022-03-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2022-03-25 | 2021-12-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2022-11-10 | 2022-09-30 | -0.6 | -0.4517 | 0.1483 | 24 | ||
2024-03-18 | 2023-12-31 | -0.1 | 0.06 | 0.16 | 160 | ||
2023-08-10 | 2023-06-30 | -0.29 | -0.52 | -0.23 | 79 | ||
2023-11-13 | 2023-09-30 | -0.26 | 0.06 | 0.32 | 123 | ||
2018-05-03 | 2018-03-31 | -0.69 | -1.03 | -0.34 | 49 | ||
2022-08-15 | 2022-06-30 | -0.6 | -0.03 | 0.57 | 95 |
Know Avenue Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avenue Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avenue Therapeutics backward and forwards among themselves. Avenue Therapeutics' institutional investor refers to the entity that pools money to purchase Avenue Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-06-30 | 75 K | Sabby Management Llc | 2024-06-30 | 37.4 K | Moss Adams Wealth Advisors Llc | 2024-09-30 | 11 K | Tower Research Capital Llc | 2024-06-30 | 3.2 K | Ubs Group Ag | 2024-06-30 | 673 | Wells Fargo & Co | 2024-06-30 | 61.0 | Royal Bank Of Canada | 2024-06-30 | 8.0 | Emfo, Llc | 2024-06-30 | 8.0 | Bank Of America Corp | 2024-06-30 | 7.0 | Jpmorgan Chase & Co | 2024-06-30 | 1.0 |
Avenue Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.84 M.Market Cap |
|
Avenue Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.61) | (5.89) | |
| Return On Capital Employed | (22.23) | (21.12) | |
| Return On Assets | (5.61) | (5.89) | |
| Return On Equity | (6.56) | (6.23) |
Determining Avenue Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Avenue Therapeutics is a good buy. For example, gross profit margin measures Avenue Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avenue Therapeutics' profitability and make more informed investment decisions.
Evaluate Avenue Therapeutics' management efficiency
Avenue Therapeutics has return on total asset (ROA) of (2.0135) % which means that it has lost $2.0135 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.351) %, meaning that it created substantial loss on money invested by shareholders. Avenue Therapeutics' management efficiency ratios could be used to measure how well Avenue Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -5.89. The Avenue Therapeutics' current Return On Capital Employed is estimated to increase to -21.12. The Avenue Therapeutics' current Other Current Assets is estimated to increase to about 129.6 K, while Total Assets are projected to decrease to under 1.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.64 | 3.33 | |
| Tangible Book Value Per Share | 4.64 | 3.33 | |
| Enterprise Value Over EBITDA | (0.02) | (0.02) | |
| Price Book Value Ratio | 1.08 | 1.13 | |
| Enterprise Value Multiple | (0.02) | (0.02) | |
| Price Fair Value | 1.08 | 1.13 | |
| Enterprise Value | 6.6 B | 4.7 B |
The management strategies employed by Avenue Therapeutics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta (0.18) |
Basic technical analysis of Avenue Stock
As of the 21st of November, Avenue Therapeutics shows the mean deviation of 3.33, and Risk Adjusted Performance of (0.06). Avenue Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Avenue Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avenue Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avenue Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avenue Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avenue Therapeutics' Outstanding Corporate Bonds
Avenue Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avenue Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avenue bonds can be classified according to their maturity, which is the date when Avenue Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| AVNT 7125 01 AUG 30 Corp BondUS05368VAA44 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US05367AAH68 Corp BondUS05367AAH68 | View | |
| AVIAGP 9 01 DEC 28 Corp BondUS05368PAA75 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View |
Understand Avenue Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Avenue Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 2.95 | |||
| Mean Deviation | 3.33 | |||
| Coefficient Of Variation | (1,052) | |||
| Standard Deviation | 4.51 | |||
| Variance | 20.3 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.95) | |||
| Treynor Ratio | 2.94 | |||
| Maximum Drawdown | 23.22 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 6.81 | |||
| Skewness | 0.5208 | |||
| Kurtosis | 1.3 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 2.95 | |||
| Mean Deviation | 3.33 | |||
| Coefficient Of Variation | (1,052) | |||
| Standard Deviation | 4.51 | |||
| Variance | 20.3 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.95) | |||
| Treynor Ratio | 2.94 | |||
| Maximum Drawdown | 23.22 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 6.81 | |||
| Skewness | 0.5208 | |||
| Kurtosis | 1.3 |
Consider Avenue Therapeutics' intraday indicators
Avenue Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Avenue Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Avenue Therapeutics Corporate Filings
F3 | 15th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 7th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Avenue Stock media impact
Far too much social signal, news, headlines, and media speculation about Avenue Therapeutics that are available to investors today. That information is available publicly through Avenue media outlets and privately through word of mouth or via Avenue internal channels. However, regardless of the origin, that massive amount of Avenue data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Avenue Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Avenue Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Avenue Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Avenue Therapeutics alpha.
Avenue Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Avenue Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Already Invested in Avenue Therapeutics?
The danger of trading Avenue Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avenue Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avenue Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avenue Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share 24.78 | Return On Assets (2.01) | Return On Equity (5.35) |
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Avenue Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.